Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Glioblastoma 80Prostatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 54Breast Neoplasms 54Esophageal Neoplasms 48Rectal Neoplasms 42Lung Neoplasms 42Brain Neoplasms 34Squamous Cell Carcinoma of Head and Neck 33Head and Neck Neoplasms 33Gliosarcoma 31Pancreatic Neoplasms 29Uterine Cervical Neoplasms 28Neoplasms 25Glioma 24Neoplasm Metastasis 23Sarcoma 22Oropharyngeal Neoplasms 21Esophageal Squamous Cell Carcinoma 20Melanoma 19Astrocytoma 18Adenocarcinoma Of Esophagus 15Stomach Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Squamous Cell 12Urinary Bladder Neoplasms 11Mouth Neoplasms 11Lymphoma, Follicular 11Central Nervous System Neoplasms 11Carcinoma 11

Interventions

Magnetic Resonance Spectroscopy 5Radiosurgery 4luprolide acetate gel depot 3enzalutamide 3Radiotherapy 3Radiation 3Leuprolide 3Goserelin 3relugolix 2gallium 68 PSMA-11 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Triptorelin Pamoate 2Specimen Handling 2Proton Therapy 2Biopsy 2radium Ra 223 dichloride 1niraparib 1histrelin 1fluciclovine F-18 1flibanserin 1entinostat 1darolutamide 1atezolizumab 1apalutamide 1abiraterone 1X-Rays 1Watchful Waiting 1Surveys and Questionnaires 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × Radiation × Clear all
NCT03274687 2026-05-20

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NRG Oncology

Phase 3 Completed
296 enrolled 29 charts
Genitourinary

Prostate Adenocarcinoma

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

University of Washington

Phase 2 Recruiting
100 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡